Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Alzheimer's disease (AD) is the primary cause of dementia, marked by amyloid plaques and tau neurodegeneration.
• Current anti-amyloid immunotherapies have limitations, necessitating novel therapeutic approaches.
• Astrocytes, key glial cells in the brain, are increasingly recognized for their role in AD pathogenesis.

Purpose of the Study:

• To introduce and validate chimeric antigen receptors expressed in astrocytes (CAR-A) as a novel therapeutic strategy for Alzheimer's disease.
• To investigate the efficacy of CAR-A in reducing amyloid pathology in vitro and in vivo.
• To elucidate the impact of CAR-A treatment on glial cell responses, including astrocytes and microglia.

Main Methods:

• Development and in vitro validation of two distinct CAR-A designs targeting amyloid pathology.
• In vivo assessment of CAR-A efficacy in reducing amyloid burden and associated pathology.
• Single-nucleus RNA sequencing (snRNA-seq) to analyze CAR-A-induced changes in glial cell populations and gene expression.

Main Results:

• Both CAR-A designs demonstrated significant reduction of amyloid pathology after plaque formation in vivo.
• CAR-A treatment effectively prevented early amyloid plaque deposition.
• snRNA-seq revealed that CAR-A induced a unique glial response, characterized by coordinated astrocyte and microglia activity, with receptor-specific effects observed in each cell type.

Conclusions:

• Chimeric antigen receptors expressed in astrocytes (CAR-A) represent a promising, disease-modifying therapeutic strategy for Alzheimer's disease.
• CAR-A therapy modulates glial responses, suggesting a novel mechanism for combating amyloid pathology.
• Further research into CAR-A holds potential for developing innovative treatments for AD and other neurodegenerative diseases.